ALX-1393 is primarily used in research and development within the field of oncology. It functions as a potent and selective inhibitor of SLC6A14, an amino acid transporter that is often overexpressed in certain types of cancer cells. By blocking this transporter, ALX-1393 disrupts the supply of essential amino acids to cancer cells, thereby inhibiting their growth and proliferation. This mechanism makes it a promising candidate for targeted cancer therapies, particularly in cancers where SLC6A14 plays a critical role in tumor progression. Additionally, its selectivity helps minimize off-target effects, potentially reducing side effects compared to traditional chemotherapy. Research is ongoing to explore its efficacy in preclinical and clinical settings, with a focus on its potential to enhance treatment outcomes for patients with aggressive or resistant cancers.